APR-246 & Azacitidine for the Treatment of TP53 Mutant Myelodysplastic Syndromes (MDS)

Condition:   MDS Interventions:   Drug: APR-246 + azacitidine;   Drug: Azacitidine Sponsor:   Aprea Therapeutics AB Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials